Announced Tue, 28 Jul · 22:39 IST
Glenmark launches Sugammadex Injection in USA market
Regulatory Product ApprovalExport Order Hard CurrencyBusiness Updates View source PDFExplain this filing
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+1.1%1-day move
₹2182.70
prior close
₹2196.40
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.7+0.7+1.0+0.8+1.1+3.0+2.2+1.6+3.5+4.7+2.9———
Up moveDown movePending
AI summary
Glenmark Pharmaceuticals Inc., USA launched Sugammadex Injection in two strengths (200 mg/2 mL and 500 mg/5 mL, 100 mg/mL). It is bioequivalent and therapeutically equivalent to Merck's BRIDION Injection. The reference market reached about $1.6 billion in annual sales in the 12 months ending May 2026. The Day 1 launch strengthens Glenmark's US injectables portfolio and hospital segment presence.
Likely market impact
Opens a new revenue stream in a large US market worth about $1.6 billion. Strengthens Glenmark's US hospital and injectables portfolio.